一種高效選擇性的化學致動劑可調控小鼠和猴子的神經元與行為
作者:
小柯機器人發布時間:2020/7/8 13:28:30
2020年7月6日出版的《自然—神經科學》發表了日本國立放射線醫學綜合研究所Takafumi Minamimoto課題組的最新研究成果。該研究發現脫氯氯氮平(DCZ)是一種有效且高選擇性的化學遺傳學致動器,可在小鼠和猴子中快速調節神經元和行為。
基於毒蕈鹼的只能由設計藥物激活的設計受體(DREADDs)提供了新的高親和力和高選擇性激動劑DCZ。陽離子發射斷層掃描顯示DCZ在小鼠和猴子中選擇性結合併佔據DREADD。在小鼠和猴子中,通過hM3Dq系統幾分鐘內遞送低劑量的DCZ(1或3μg/ 每 kg)可增強神經元活性。肌肉注射DCZ(100μg/ 每kg)可逆地誘導前額葉皮層中表達hM4Di猴子的空間工作記憶缺陷。DCZ代表一種有效、高選擇性、代謝穩定和快速作用的DREADD激動劑,可在小鼠和非人類靈長類動物中發揮多種用途。
研究人員表示,只能由設計藥物激活的設計受體(DREADDs)可提供對細胞信號傳導、神經元活動和行為的遠程可逆調控。儘管基於毒蕈鹼的DREADD與氯氮平-N-氧化物(CNO)的組合已被廣泛使用,但其緩慢的動力學、代謝障礙和CNO的脫靶效應仍亟待改進。
附:英文原文
Title: Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys
Author: Yuji Nagai, Naohisa Miyakawa, Hiroyuki Takuwa, Yukiko Hori, Kei Oyama, Bin Ji, Manami Takahashi, Xi-Ping Huang, Samuel T. Slocum, Jeffrey F. DiBerto, Yan Xiong, Takuya Urushihata, Toshiyuki Hirabayashi, Atsushi Fujimoto, Koki Mimura, Justin G. English, Jing Liu, Ken-ichi Inoue, Katsushi Kumata, Chie Seki, Maiko Ono, Masafumi Shimojo, Ming-Rong Zhang, Yutaka Tomita, Jin Nakahara, Tetsuya Suhara, Masahiko Takada, Makoto Higuchi, Jian Jin, Bryan L. Roth, Takafumi Minamimoto
Issue&Volume: 2020-07-06
Abstract: The chemogenetic technology designer receptors exclusively activated by designer drugs (DREADDs) afford remotely reversible control of cellular signaling, neuronal activity and behavior. Although the combination of muscarinic-based DREADDs with clozapine-N-oxide (CNO) has been widely used, sluggish kinetics, metabolic liabilities and potential off-target effects of CNO represent areas for improvement. Here, we provide a new high-affinity and selective agonist deschloroclozapine (DCZ) for muscarinic-based DREADDs. Positron emission tomography revealed that DCZ selectively bound to and occupied DREADDs in both mice and monkeys. Systemic delivery of low doses of DCZ (1 or 3μgperkg) enhanced neuronal activity via hM3Dq within minutes in mice and monkeys. Intramuscular injections of DCZ (100μgperkg) reversibly induced spatial working memory deficits in monkeys expressing hM4Di in the prefrontal cortex. DCZ represents a potent, selective, metabolically stable and fast-acting DREADD agonist with utility in both mice and nonhuman primates for a variety of applications.
DOI: 10.1038/s41593-020-0661-3
Source: https://www.nature.com/articles/s41593-020-0661-3